Navigation Links
GeneTex to Release New Antibodies for the Study of DNA Repair in Zebrafish
Date:3/14/2013

IRVINE, Calif., March 14, 2013 /PRNewswire/ -- GeneTex, a leading manufacturer of high-quality antibodies, is pleased to announce that it will be launching new antibodies against phosphorylated Histone H2A.X and p53 designed for use with zebrafish samples.

(Photo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b)

The zebrafish is being increasingly utilized as a model organism to study DNA repair. The zebrafish genome contains nearly all of the genes involved in the different DNA repair pathways, including the genes for the components of the p53-mediated damage recognition pathway. Furthermore, the embryos can easily be treated with UV or ionizing irradiation to induce DNA damage.  Importantly, the study of individual DNA damage recognition and repair factors is possible with shRNA- or morpholino-based approaches that are established techniques in the zebrafish field.

GeneTex is excited to contribute to zebrafish DNA damage recognition and repair research by offering these two new antibodies. Phosphorylated histone H2A.X is extremely useful as an early marker of double-strand breaks that can be used to assess the extent of DSB repair. The p53 antibody will be immensely valuable for those researchers studying DNA damage and apoptotic mechanisms, with the logical extension into tumorigenesis. These two reagents represent just the beginning of GeneTex's efforts to establish a diverse catalog of antibody products that perform in the zebrafish system. Therefore, GeneTex is pleased to announce the launch of these new antibodies against phosphorylated H2A.X and p53 that have been developed specifically for use with zebrafish.

GeneTex's Histone H2A.X (phospho Ser139) antibody has been validated for immunohistochemistry using both whole-mount and paraffin-embedded zebrafish embryos. The p53 antibody has been validated for western blotting and immunohistochemistry using zebrafish tissues. UV irradiation results in a marked increase in the intensity of the signal detected by both products, which demonstrates the specificity of these antibodies. For additional information on GeneTex, Inc. and its zebrafish antibodies, please call toll-free 877-GENETEX (436-3839) or visit www.genetex.com/zebrafish.

About GeneTex, Inc.

GeneTex, Inc. is an antibody company founded in 1997 by a group of internationally renowned academic scientists. They strive to produce the highest-quality antibodies and reagents. Their primary and secondary antibodies are created through a process involving extensive research, development and validation.  GeneTex's catalog has grown to over 55,000 primary antibodies and all are backed by a 100% Satisfaction Guarantee. 

Corporate Mission

We strive to serve and accelerate life science research by creating essential life science tools where quality can be found in every vial.


'/>"/>
SOURCE GeneTex
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
4. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
5. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
6. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
7. ShelfX Releases A Fridge That Knows What You Took
8. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
9. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
10. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
11. Dynatronics To Release Fiscal Third Quarter Results Tuesday, May 15, 2012; Conference Call set for 3:30 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is ... from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... body recognizes its raw form (unlike the synthetically made options that are on the ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... breakthrough topical cream that’s the first in a new class of photodynamic cosmetics ... overall appearance of skin, visibly reduce outward signs of aging, and minimize the ...
(Date:4/25/2017)... ... 2017 , ... As President Trump challenges the status quo ... administration could impact the employee benefits industry. James Slotnick, AVP, Government Relations, for ... make it through Congress. His discussion will focus on the current state of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... targets, they rely on contracted partners to help with process innovation in drug ... combined drug formulation experience along with state-of-the-art analytical equipment in support of their ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
Breaking Medicine News(10 mins):